Applications of 1-(2-Chlorophenyl)-N-Methyl-N-(1-Methylpropyl)-3-Isoquinolinecarboxamide in Industrial Manufacturing

As the original producer of 1-(2-Chlorophenyl)-N-Methyl-N-(1-Methylpropyl)-3-Isoquinolinecarboxamide, we supply this specialized intermediate directly to key industrial sectors. Our clients leverage its properties in complex synthesis steps that demand tightly controlled process parameters and adherence to comprehensive international standards. The following sections detail principal use cases in real industrial supply chains, referring to specific regulatory, quality, and production frameworks.

1. Active Pharmaceutical Ingredient Synthesis for CNS Drug Candidates

Major pharmaceutical manufacturers utilize this compound as an advanced intermediate in multi-step syntheses targeting central nervous system modulators, especially those in the isoquinoline carboxamide class. It typically enters the production protocol during late-stage molecular assembly, following strict control of reaction temperature, pressure, and solvent systems to ensure enantiopurity and impurity profile compliance. Selection of this intermediate allows for customization of molecular scaffolds through further substitution or cyclization, progressing toward high-value investigational APIs destined for human clinical trials and authorized prescriptions under stringent regulatory scrutiny.

Industry compliance standards

• ICH Q7: Good Manufacturing Practice (GMP) Guidance for Active Pharmaceutical Ingredients
• EU GMP Part II: Basic Requirements for Active Substances
• United States Pharmacopeia (USP) guidelines where relevant for intermediates
• ISO 9001:2015 Quality Management in manufacture and QC

Typical usage ratio

• Stoichiometric to 10% excess relative to nucleophilic partners in final amide coupling; actual ratio depends on target yield and byproduct control

Downstream process integration

• Introduced during penultimate step of active molecule assembly before final deprotection and crystallization; stringent dry and clean-room conditions maintained throughout handling

Final product types

• Central nervous system API candidates (e.g., experimental anxiolytics, antipsychotics)
• Clinical trial materials for new drug applications
• Reference standards for regulatory submission batches

2. Custom Fine Chemical Intermediates for Crop Protection Agents

Agrochemical formulators source this isoquinolinecarboxamide derivative as a tailored building block for the synthesis of selective herbicidal and pesticidal actives. It specifically supports assembly of active ingredients with targeted biological modes of action, including those inhibiting plant-specific kinases or hormonal pathways. Industrial operators deploy highly automated reactors to combine the intermediate in aqueous or organic media, with continuous analysis for conversion rates, residual solvents, and trace impurity content. The compliance focus remains both on process safety and on downstream environmental risk assessment for residue-limited use in regulated agriculture.

Industry compliance standards

• FAO/WHO Specification for Pesticide Active Ingredients (FAO/WHO)
• REACH (Registration, Evaluation, Authorisation and Restriction of Chemicals) standards for synthetic intermediates
• ISO 14001:2015 Environmental Management
• Local ecotoxicological risk assessment and workplace safety guidelines

Typical usage ratio

• 5–15% weight percentage relative to total synthetic mass in multi-step synthesis flows; higher usage for batch modes, lower in continuous reaction setups

Downstream process integration

• Fed directly into heterocyclic coupling stages, under inert atmosphere; followed by liquid–liquid extraction and solvent exchanges before active ingredient isolation

Final product types

• Herbicidal actives for post-emergence weed control
• Systemic fungicide APIs for seed treatments
• Custom pesticide actives for local registration

3. Advanced Research Reagents in Medicinal Chemistry and High-Throughput Screening

Specialty chemical suppliers and pharmaceutical research institutes incorporate this compound into discovery-phase medicinal chemistry, particularly for preparation of focused compound libraries. Industrial experimenters harness its reactivity for rapid scaffolding and late-stage diversification in pilot-scale production of screening candidates. Batch records document each scale-up, with particular attention to reaction reproducibility, containment of hazardous byproducts, and standardization for downstream analytical validation and toxicological profiling. The use must align closely with laboratory safety and international chemical handling standards.

Industry compliance standards

• OECD Good Laboratory Practice (GLP) Principles for non-clinical safety evaluation
• ISO/IEC 17025:2017 for analytical laboratory competence
• UN Globally Harmonized System (GHS) for chemical labeling and handling
• European Chemicals Agency (ECHA) notification for non-commercial synthesis

Typical usage ratio

• 0.5–2.5 mmol per reaction vessel for bench scale synthesis; up to 250 g per batch in pilot library generation; scale adapted to target throughput and hazard assessment

Downstream process integration

• Dosed directly into amide bond-forming, cyclization, or Suzuki coupling experiments as primary scaffold or as capping agent in lead candidate assembly pathways

Final product types

• Compound libraries for bioactivity screening assays
• Reference standards for pharmacological profiling
• Quality control samples for HPLC/MS validation

4. Specialty Intermediate for Functional Materials R&D

Advanced materials laboratories and industrial R&D centers employ this compound as a precursor in development of functional small-molecule additives for electronics and imaging technologies. The selective introduction of the chlorophenyl-isoquinoline structure enhances charge transport, thermal stability, and molecular rigidity in a range of prototype photonic and electronic components. During upscaling, process chemists control the stoichiometry, solvent polarity, and post-reaction purification to ensure uniformity and minimize byproducts. The facility operates under documented quality and environmental systems suitable for functional material innovation, with regular audits to confirm traceability and IP protection.

Industry compliance standards

• IECQ QC 080000: Hazardous Substance Process Management (HSPM)
• ISO 9001:2015 for material research and development
• RoHS (Restriction of Hazardous Substances) compliance where material may enter electronics supply chain
• REACH requirements for specialty chemical intermediates in R&D

Typical usage ratio

• 2–10 mol% relative to core monomers in advanced electronics precursor synthesis; precise ratio based on intended electronic or optical functionality

Downstream process integration

• Integrated into step-growth or condensation polymerization batches for prototype OLEDs or organic semiconductors, followed by flash chromatography and spectroscopic verification

Final product types

• OLED precursor entities
• Small-molecule dopants for organic transistors
• Functional imaging markers for advanced diagnostics